胃灵合剂联合瑞巴派特治疗胃溃疡的临床研究
|
摘要
目的探讨胃灵合剂联合瑞巴派特片治疗胃溃疡患者的临床疗效。方法选取2014年3月—2017年3月于郑州市第七人民医院就诊的176例胃溃疡患者进行研究,随机将患者分为对照组(88例)和治疗组(88例)。对照组患者口服瑞巴派特片,1片/次,3次/d;治疗组患者在对照组基础上口服胃灵合剂,20 mL/次,3次/d。两组均连续治疗4周。观察两组患者的临床疗效,比较两组的血管内皮生长因子(VEGF)、前列腺素E2(PGE2)、基质金属蛋白酶-9(MMP-9)水平,药物不良反应发生率和治疗后6、12个月胃溃疡复发率。结果治疗后,对照组和治疗组的总有效率分别为86.36%、96.59%,两组总有效率比较差异具有统计学意义(P<0.05)。治疗后,两组血清VEGF、PGE2水平均显著升高,MMP-9血清水平显著降低(P<0.05);且治疗组各血清指标显著优于对照组(P<0.05)。治疗期间,治疗组的药物不良反应发生率为3.41%,明显低于对照组的12.50%,两组比较差异具有统计学意义(P<0.05)。治疗后,治疗组患者6、12个月胃溃疡复发率均显著低于对照组,两组比较差异具有统计学意义(P<0.05)。结论胃灵合剂联合瑞巴派特片治疗胃溃疡疗效显著,不良反应发生率和复发率低,具有一定的临床推广应用价值。
Objective To investigate the clinical efficacy of Weiling Heji combined with Rebamipide Tablets in treatment of gastric ulcer. Methods Patients(176 cases) with gastric ulcer in The 7th Hospital of Zhengzhou from March 2014 to March 2017 were divided into control(88 cases) and treatment(88 cases) groups. Patients in the control group were po administered with Rebamipide Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Weiling Heji on the basis of the control group, 20 mL/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the levels of VEGF, PGE2, and MMP-9, the incidence of adverse drug reactions, and the recurrence rate of gastric ulcer6 and 12 months after treatment in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment group were 86.36% and 96.59%, and there were differences between two groups(P < 0.05). After treatment, VEGF and PGE2 levels in two groups were significantly increased, but MMP-9 levels in two groups was significantly decreased(P < 0.05). After treatment, the serum indexes in the treatment group were significantly better than those in the control group(P < 0.05). After treatment,incidence of adverse drug reactions in the treatment group was 3.41%, which was significantly lower than 12.50% in the control group, and there were differences between two groups(P < 0.05). After treatment, the recurrence rate of gastric ulcer in the treatment group was significantly lower than that in the control group at 6 and 12 months, and there were differences between two groups(P <0.05). Conclusion Weiling Heji combined with Rebamipide Tablets has significant clinical efficacy in treatment of gastric ulcer, with low incidence of adverse reactions and recurrence rate, which has a certain clinical application value.
Objective To investigate the clinical efficacy of Weiling Heji combined with Rebamipide Tablets in treatment of gastric ulcer. Methods Patients(176 cases) with gastric ulcer in The 7th Hospital of Zhengzhou from March 2014 to March 2017 were divided into control(88 cases) and treatment(88 cases) groups. Patients in the control group were po administered with Rebamipide Tablets, 1 tablet/time, three times daily. Patients in the treatment group were po administered with Weiling Heji on the basis of the control group, 20 mL/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the levels of VEGF, PGE2, and MMP-9, the incidence of adverse drug reactions, and the recurrence rate of gastric ulcer6 and 12 months after treatment in two groups were compared. Results After treatment, the clinical efficacy in the control and treatment group were 86.36% and 96.59%, and there were differences between two groups(P < 0.05). After treatment, VEGF and PGE2 levels in two groups were significantly increased, but MMP-9 levels in two groups was significantly decreased(P < 0.05). After treatment, the serum indexes in the treatment group were significantly better than those in the control group(P < 0.05). After treatment,incidence of adverse drug reactions in the treatment group was 3.41%, which was significantly lower than 12.50% in the control group, and there were differences between two groups(P < 0.05). After treatment, the recurrence rate of gastric ulcer in the treatment group was significantly lower than that in the control group at 6 and 12 months, and there were differences between two groups(P <0.05). Conclusion Weiling Heji combined with Rebamipide Tablets has significant clinical efficacy in treatment of gastric ulcer, with low incidence of adverse reactions and recurrence rate, which has a certain clinical application value.
引文
[1]孙玉鹤,张春凤.胃溃疡研究进展[J].亚太传统医药,2014,10(11):46-49.
[2]晁宏军.胃溃疡的病因及防治概述[J].临床合理用药杂志,2012,5(9):147.
[3]刘永军,梅浙川.抗溃疡药瑞巴匹特[J].药学进展,2005,29(1):48.
[4]陈明.浅谈中药胃灵合剂治脾胃病[J].中国社区医师,2007,23(6):8.
[5]葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社,2013:369-374.
[6]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:151-155.
[7]周永健,聂玉强,李瑜元,等.消化性溃疡并发出血危险因素研究[J].广州医药,2001,32(6):15-17.
[8]任长庆,高梦先.胃溃疡与幽门螺杆菌感染及胃粘膜肠上皮化生的关系[J].人民军医,2000,43(11):650-651.
[9]崔东来,姚希贤.消化性溃疡的并发症及防治[J].中国全科医学,2000,3(1):12-13.
[10]王海燕.瑞巴匹特-一种新型抗感染和抗溃疡药物的研究进展[J].医学综述,2000,6(9):422-423.
[11]袁兴洪.胃溃疡患者胃粘膜血管内皮生长因子表达水平研究[J].四川医学,2012,33(3):457-458.
[12]胡义亭,甄承思,邢国章,等.消化性溃疡患者转化生长因子α、表皮生长因子和前列腺素E2的关系[J].世界华人消化杂志,2002,10(1):43-47.
[13]赵景润,任晓燕,李复领,等.MMP-9、TIMP-1在胃溃疡组织中的表达及与组织学的关系[J].胃肠病学和肝病学杂志,2012,21(1):52-54.
[2]晁宏军.胃溃疡的病因及防治概述[J].临床合理用药杂志,2012,5(9):147.
[3]刘永军,梅浙川.抗溃疡药瑞巴匹特[J].药学进展,2005,29(1):48.
[4]陈明.浅谈中药胃灵合剂治脾胃病[J].中国社区医师,2007,23(6):8.
[5]葛均波,徐永健.内科学[M].第8版.北京:人民卫生出版社,2013:369-374.
[6]郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:151-155.
[7]周永健,聂玉强,李瑜元,等.消化性溃疡并发出血危险因素研究[J].广州医药,2001,32(6):15-17.
[8]任长庆,高梦先.胃溃疡与幽门螺杆菌感染及胃粘膜肠上皮化生的关系[J].人民军医,2000,43(11):650-651.
[9]崔东来,姚希贤.消化性溃疡的并发症及防治[J].中国全科医学,2000,3(1):12-13.
[10]王海燕.瑞巴匹特-一种新型抗感染和抗溃疡药物的研究进展[J].医学综述,2000,6(9):422-423.
[11]袁兴洪.胃溃疡患者胃粘膜血管内皮生长因子表达水平研究[J].四川医学,2012,33(3):457-458.
[12]胡义亭,甄承思,邢国章,等.消化性溃疡患者转化生长因子α、表皮生长因子和前列腺素E2的关系[J].世界华人消化杂志,2002,10(1):43-47.
[13]赵景润,任晓燕,李复领,等.MMP-9、TIMP-1在胃溃疡组织中的表达及与组织学的关系[J].胃肠病学和肝病学杂志,2012,21(1):52-54.